Coforge Shares Jump 7% as Q1 FY27 Profit Soars 63% and Order Book Hits Record High
Coforge's Q1 profit surges 63% YoY, boosting shares by 7% amid strong digital transformation demand.
Welcome to VTechX Hub
Sign in to bookmark insights, track signals, and get a personalized feed.
Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
Encora has merged with Coforge.
Coforge's Q1 profit surges 63% YoY, boosting shares by 7% amid strong digital transformation demand.
VTechX HubIt is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
SourceAsk VTechX Intelligence about Encora
Deep-dive analysis with verified sources